EMD Serono, Inc. is an affiliate of Merck KGaA, Darmstadt, Germany. Together, EMD Serono and its affiliates offer potential partners a solid foundation upon which to build mutually rewarding relationships.
EMD Serono and Theratechnologies
entered into a collaboration and licensing agreement for the exclusive rights, by EMD Serono, Inc., to EGRIFTA® (tesamorelin for injection)
in the United States. EGRIFTA®
was approved by the FDA in November of 2010.
EGRIFTA® is a registered trademark of Theratechnologies Inc.
© 2011 EMD Serono, Inc. All rights reserved.